Breast (Edinburgh, Scotland) · 2025
Standardized patient coaching improves therapy persistence in patients with hormone receptor-positive, HER2-negative advanced/metastatic breast cancer treated with abemaciclib.
СтатьяРандомизированное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Welslau Manfred, Fasching Peter A, Semmler-Lins Nicole, Mueller Lothar, Belleville Erik, Rieger Lorenz, Uhrig Sabrina, Zahn Mark-Oliver, Lex Benno, Uleer Christoph, Deuerling Natalija, Hesse Tobias, Langanke Dagmar, Häberle Lothar, Tesch Hans
Аннотация
INTRODUCTION: Therapy adherence is critical, particularly for patients with breast cancer undergoing oral endocrine therapies. The use of combination regimes, such as CDK4/6 inhibitors, has introduced additional side effects, which can affect adherence. A structured patient coaching and communication tool may positively affect therapy adherence.
METHODS: The IMPACT study (NCT04030728) was a randomized trial including patients with advanced breast cancer (aBC) receiving abemaciclib as part of routine clinical care. The study examined the influence of structured coaching on patient adherence. Participants were randomized to receive therapy management incorporating the Multinational Association of Supportive Care in Cancer (MASCC) Oral Agent Teaching Tool (MOATT©) or local standard of care practice (LSOC). The primary endpoint was the persistence rate at week 24 (PR24). Secondary endpoints included time to therapy discontinuation (TTD) and quality of life.
RESULTS: A total of 201 patients were randomized and initiated abemaciclib therapy. By week 24, 22 (10.9 %) patients had permanently discontinued abemaciclib for reasons other than progression or death: 14 (14.1 %) in the LSOC arm and 8 (7.8 %) in the MOATT© arm. PR24 was 68.9 % (95 % CI: 58.3-78.2) in the LSOC arm and 81.6 % (95 % CI: 72.5-88.7) in the MOATT© arm, yielding an odds ratio of 2.01 (95 % CI: 1.02-3.96; P = 0.04). TTD showed a hazard ratio of 0.59 (95 % CI: 0.32-1.07), favoring the MOATT© arm. No significant differences in quality of life between study arms were observed.
CONCLUSION: Individual patient coaching based on MOATT© demonstrated improved PR24 for patients undergoing abemaciclib treatment for aBC.
METHODS: The IMPACT study (NCT04030728) was a randomized trial including patients with advanced breast cancer (aBC) receiving abemaciclib as part of routine clinical care. The study examined the influence of structured coaching on patient adherence. Participants were randomized to receive therapy management incorporating the Multinational Association of Supportive Care in Cancer (MASCC) Oral Agent Teaching Tool (MOATT©) or local standard of care practice (LSOC). The primary endpoint was the persistence rate at week 24 (PR24). Secondary endpoints included time to therapy discontinuation (TTD) and quality of life.
RESULTS: A total of 201 patients were randomized and initiated abemaciclib therapy. By week 24, 22 (10.9 %) patients had permanently discontinued abemaciclib for reasons other than progression or death: 14 (14.1 %) in the LSOC arm and 8 (7.8 %) in the MOATT© arm. PR24 was 68.9 % (95 % CI: 58.3-78.2) in the LSOC arm and 81.6 % (95 % CI: 72.5-88.7) in the MOATT© arm, yielding an odds ratio of 2.01 (95 % CI: 1.02-3.96; P = 0.04). TTD showed a hazard ratio of 0.59 (95 % CI: 0.32-1.07), favoring the MOATT© arm. No significant differences in quality of life between study arms were observed.
CONCLUSION: Individual patient coaching based on MOATT© demonstrated improved PR24 for patients undergoing abemaciclib treatment for aBC.